<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706159</url>
  </required_header>
  <id_info>
    <org_study_id>NN8717-3946</org_study_id>
    <secondary_id>2011-001568-22</secondary_id>
    <secondary_id>U1111-1120-3824</secondary_id>
    <nct_id>NCT01706159</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis</brief_title>
  <official_title>A Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>Croatia: Ministry of Health and Social Care</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health Ukraine</authority>
    <authority>Russia: Federal Service for Control of Health Care and Social Development</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the effect of
      recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active
      ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial screening data did not support the medical hypothesis
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Endoscopic remission defined as a modified Baron score of 0</measure>
    <time_frame>At week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission (clinical, endoscopic)</measure>
    <time_frame>At week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>Weeks 0 - 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) systemically</measure>
    <time_frame>0-72 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration (Cmax) systemically</measure>
    <time_frame>0-72 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Inflammation</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>rFXIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant factor XIII</intervention_name>
    <description>rFXIII will be administered as intravenous (i.v.) injections once every second week at a dose of 35 IU/kg</description>
    <arm_group_label>rFXIII</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be administered as intravenous (i.v.) injections once every second week at a dose of 35 IU/kg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ulcerative colitis for at least 3 months from the time of initial
             diagnosis. The diagnosis must have been confirmed by historical endoscopy and
             histology. The severity of disease must have been confirmed by endoscopy at screening

          -  Currently receiving oral aminosalicylates at approved doses for at least 6 weeks of
             at least 2g/day. Doses of oral aminosalicylates should be stable for at least two
             weeks prior to dosing (Visit 2)

        Exclusion Criteria:

          -  Diagnosis of UC limited to the rectum (ulcerative proctitis only, defined as  15 cm
             from the anal verge)

          -  Requiring hospitalisation for current episode of severe UC

          -  Use of biologic therapies for the treatment of UC within 12 weeks prior to dosing
             (Visit 2)

          -  Treatment failures to anti-tumour necrosis factor-alfa (anti-TNF-a) agents (e.g.
             infliximab, adalimumab)

          -  Use of immunosuppressant agents (e.g. azathioprine) within 4 weeks prior to dosing
             (Visit 2)

          -  Use of corticosteroids (oral, intravenous (i.v.), intramuscular (i.m.), or rectal )
             within 14 days prior to dosing (Visit 2)

          -  Use of enemas (corticosteroid or aminosalicylate) within 14 days prior to screening
             (Visit 1)

          -  Use of cyclosporine, tacrolimus, D-penicillamine, leflunomide, methotrexate,
             mycophenolate mofetil, or thalidomide within 4 weeks prior to dosing (Visit 2)

          -  Currently receiving total parenteral nutrition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Francisco</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <zip>H5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lipetsk</city>
        <zip>398055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knipropetrovsk</city>
        <zip>49044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
